1
|
Asai S, Suzuki M, Hara R, Hirano Y, Nagamine S, Kaneko T, Suto T, Okano T, Yoshioka Y, Hirao M, Wakabayashi H, Fujibayashi T, Watanabe T, Takakubo Y, Ishikawa H, Nasu Y, Takemoto T, Kato T, Torikai E, Koyama K, Takagi H, Fujiwara T, Sobue Y, Ohashi Y, Nishiume T, Terabe K, Kojima M, Kojima T, Imagama S. Comparison of effectiveness of methotrexate in patients with late-onset versus younger-onset rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J). Mod Rheumatol 2024:roae027. [PMID: 38491996 DOI: 10.1093/mr/roae027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Accepted: 02/17/2024] [Indexed: 03/18/2024]
Abstract
OBJECTIVE To compare the effectiveness of methotrexate (MTX) as initial therapy in patients with late-onset and younger-onset rheumatoid arthritis (LORA and YORA). METHODS Of 114 patients with YORA and 96 patients with LORA, defined as RA occurring at ≥65 years of age, enrolled in a multicentre RA inception cohort study, 71 and 66 patients who had been followed up to 6 months after starting MTX treatment were included in this study. RESULTS Proportions of patients on MTX treatment at 6 months were 96% and 92% in the YORA and LORA groups, respectively. Despite lower doses of MTX in the LORA group compared with the YORA group, no significant difference was observed in clinical disease activity index scores between the two groups throughout the follow-up period. The proportion of patients in clinical disease activity index remission at 6 months was 35% in both groups. Logistic regression analysis revealed that knee joint involvement and high Health Assessment Questionnaire-Disability Index were significant negative predictors of achieving clinical disease activity index remission at 6 months in the LORA group. CONCLUSION Observations up to 6 months revealed that the effectiveness of MTX administered based on rheumatologist discretion in patients with LORA is comparable to that in patients with YORA in clinical settings.
Collapse
Affiliation(s)
- Shuji Asai
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
| | - Mochihito Suzuki
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
| | - Ryota Hara
- Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara, Japan
| | - Yuji Hirano
- Department of Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan
| | - Satomi Nagamine
- Department of Orthopedic Surgery, Faculty of Medicine, Saga University, Saga, Japan
| | - Tetsuya Kaneko
- Department of Orthopedic Surgery, Japan Red Cross Society Fukaya Red Cross Hospital, Fukaya, Saitama, Japan
| | - Takahito Suto
- Department of Orthopedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
| | - Tadashi Okano
- Center for Senile Degenerative Disorders, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
| | - Yutaka Yoshioka
- Department of Rheumatology, Handa City Hospital, Handa, Aichi, Japan
| | - Makoto Hirao
- Department of Orthopedic Surgery, National Hospital Organization, Osaka Minami Medical Center, Kawachinagano, Osaka, Japan
| | - Hiroki Wakabayashi
- Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan
| | | | - Tatsuo Watanabe
- Department of Orthopedic Surgery, Daido Hospital, Nagoya, Aichi, Japan
| | - Yuya Takakubo
- Department of Rehabilitation, Yamagata University Faculty of Medicine, Yamagata, Japan
| | - Hajime Ishikawa
- Department of Rheumatology, Niigata Rheumatic Center, Shibata, Niigata, Japan
| | - Yoshihisa Nasu
- Department of Orthopedic Surgery, Okayama University Hospital, Okayama, Japan
| | - Toki Takemoto
- Department of Orthopedic Surgery, Anjo Kosei Hospital, Anjo, Aichi, Japan
| | | | - Eiji Torikai
- Department of Rheumatology, Iwata City Hospital, Iwata, Shizuoka, Japan
| | - Kensuke Koyama
- Department of Orthopedic Surgery, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Hideki Takagi
- Department of Orthopedic Surgery, Nagoya Central Hospital, Nagoya, Aichi, Japan
| | - Toshifumi Fujiwara
- Department of Orthopedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Yasumori Sobue
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
| | - Yoshifumi Ohashi
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
| | - Tsuyoshi Nishiume
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
| | - Kenya Terabe
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
| | | | - Toshihisa Kojima
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
- Department of Orthopedic Surgery and Rheumatology, National Hospital Organization, Nagoya Medical Center, Nagoya, Aichi, Japan
| | - Shiro Imagama
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
| |
Collapse
|
2
|
Suzuki M, Asai S, Hara R, Hirano Y, Nagamine S, Kaneko T, Sakane H, Okano T, Yoshioka Y, Tsuji S, Wakabayashi H, Takakubo Y, Takemoto T, Fujibayashi T, Watanabe T, Kato T, Ishikawa H, Nasu Y, Torikai E, Kaneko A, Takagi H, Fujiwara T, Kihira D, Hattori K, Kishimoto K, Ohashi Y, Sobue Y, Yokota Y, Nishiume T, Terabe K, Takahashi N, Kojima M, Imagama S, Kojima T. Choice of and response to treatment in patients with early-diagnosed rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J). J Orthop Sci 2023:S0949-2658(23)00090-8. [PMID: 37076376 DOI: 10.1016/j.jos.2023.03.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Revised: 12/28/2022] [Accepted: 03/28/2023] [Indexed: 04/21/2023]
Abstract
OBJECTIVE Various guidelines recommend that patients with early rheumatoid arthritis (RA) try to achieve clinical remission within 6 months, and early therapeutic intervention is important to this end. This study aimed to investigate short-term treatment outcomes of patients with early-diagnosed RA in clinical practice and to examine predictive factors for achieving remission. METHODS Of the 210 patients enrolled in the multicenter RA inception cohort, 172 patients who were followed up to 6 months after treatment initiation (baseline) were included. Logistic regression analysis was used to examine the impact of baseline characteristics on achievement of Boolean remission at 6 months. RESULTS Participants (mean age, 62 years) initiated treatment after a mean of 19 days from RA diagnosis. At baseline and 3 and 6 months after treatment initiation, proportions of patients using methotrexate (MTX) were 87.8%, 89.0%, and 88.3%, respectively, and rates of Boolean remission were 1.8%, 27.8%, and 34.5%, respectively. Multivariate analysis revealed that physician global assessment (PhGA) (Odds ratio (OR): 0.84, 95% confidence interval (CI): 0.71-0.99) and glucocorticoid use (OR: 0.26, 95% CI: 0.10-0.65) at baseline were independent factors that predicted Boolean remission at 6 months. CONCLUSION After a diagnosis of RA, satisfactory therapeutic effects were achieved at 6 months after the initiation of treatment centered on MTX according to the treat to target strategy. PhGA and glucocorticoid use at treatment initiation are useful for predicting the achievement of treatment goals.
Collapse
Affiliation(s)
- Mochihito Suzuki
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Shuji Asai
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
| | - Ryota Hara
- Rheumatology Clinic and Department of Orthopaedic Surgery, Nara Medical University, Nara, Japan
| | - Yuji Hirano
- Department of Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
| | - Satomi Nagamine
- Department of Orthopaedic Surgery, Faculty of Medicine, Saga University, Saga, Japan
| | - Tetsuya Kaneko
- Department of Orthopaedic Surgery, Japan Red Cross Society Fukaya Red Cross Hospital, Saitama, Japan
| | - Hideo Sakane
- Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Gunma, Japan
| | - Tadashi Okano
- Department of Orthopaedic Surgery, Osaka Metropolitan University, Osaka, Japan
| | - Yutaka Yoshioka
- Department of Rheumatology, Handa City Hospital, Handa, Japan
| | - Shigeyoshi Tsuji
- Department of Orthopaedic Surgery, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan
| | - Hiroki Wakabayashi
- Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan
| | - Yuya Takakubo
- Department of Orthopedic Surgery, Faculty of Medicine, Yamagata University, Yamagata, Japan
| | - Toki Takemoto
- Department of Orthopaedic Surgery, Anjo Kosei Hospital, Anjo, Japan
| | | | - Tatsuo Watanabe
- Department of Orthopaedic Surgery, Daido Hospital, Nagoya, Japan
| | | | - Hajime Ishikawa
- Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan
| | - Yoshihisa Nasu
- Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Eiji Torikai
- Department of Rheumatology, Iwata City Hospital, Iwata, Japan
| | - Atsushi Kaneko
- Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan
| | - Hideki Takagi
- Department of Orthopedic Surgery, Nagoya Central Hospital, Aichi, Japan
| | - Toshifumi Fujiwara
- Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Daisuke Kihira
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; Kato Orthopaedic Clinic, Okazaki, Japan
| | - Kyosuke Hattori
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Orthopaedic Surgery, Toyota Kosei Hospital, Aichi, Japan
| | - Kenji Kishimoto
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yoshifumi Ohashi
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yasumori Sobue
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Rheumatology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan
| | - Yutaka Yokota
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Orthopedic Surgery, Ichinomiya Municipal Hospital, Aichi, Japan
| | - Tsuyoshi Nishiume
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Orthopedic Surgery, Okazaki City Hospital, Aichi, Japan
| | - Kenya Terabe
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Nobunori Takahashi
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Orthopaedic Surgery, Aichi Medical University Hospital, Aichi, Japan
| | - Masayo Kojima
- National Center for Geriatrics and Gerontology, Aichi, Japan
| | - Shiro Imagama
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Toshihisa Kojima
- Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
3
|
Ikarashi A, Murakami Y, Toshiyasu T, Yoshioka M, Kamima T, Tokumasu K, Nakano M, Hashimoto T, Oguchi M, Yoshioka Y. Prediction of Late Xerostomia after Radiotherapy by Integrating Dosiomics and Conventional Predictive Factors in Patients With Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Murakami Y, Murakami Y, Kamima T, Abo N, Takahashi T, Kaneko M, Nakano M, Matsubayashi F, Harada A, Taguchi S, Hashimoto T, Oguchi M, Yoshioka Y. Dosimetric Comparison Between 3D Conformal Radiation Therapy Plus Electron Boost and Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Left-Sided Breast Cancer Patients With a Potential Risk of Radiation-Induced Cardiac Toxicity. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1435] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Miyauchi H, Tanaka Y, Takahashi K, Nakano M, Hasegawa T, Hashimoto M, Hashimoto T, Oguchi M, Yoshioka Y. Development of Novel Image Processing System Using Super-Resolution to Reduce Cone-Beam CT Imaging Dose in Radiation Therapy. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Murakami Y, Soyano T, Kozuka T, Ushijima M, Koizumi Y, Miyauchi H, Kaneko M, Nakano M, Kamima T, Hashimoto T, Oguchi M, Yoshioka Y. Can Dosiomics Features Be Relevant Predictive Factors for Biochemical Recurrence After Radiotherapy in Prostate Cancer Patients? Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Takeuchi T, Nishikawa K, Yamada F, Ohshima S, Inoue M, Yoshioka Y, Yamanaka H. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics. Mod Rheumatol 2021; 32:718-727. [PMID: 34918129 DOI: 10.1093/mr/roab068] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 08/12/2021] [Accepted: 08/15/2021] [Indexed: 12/24/2022]
Abstract
OBJECTIVES The aim of this post-marketing surveillance (PMS) study is to evaluate the real-world safety and efficacy of CT-P13, the first biosimilar of infliximab (IFX). METHODS Japanese patients with rheumatoid arthritis were prospectively registered from November 2014 and followed up for 1 year. RESULTS Of 794 patients in the analysis set, 318 patients naïve to biological disease-modifying antirheumatic drugs (bDMARDs) showed an immediate decrease in Disease Activity Score in 28 joints with C-reactive protein (DAS28-CRP) and increased remission rate (DAS28-CRP < 2.6). In patients who switched from IFX to CT-P13 for non-medical reasons (n = 374), the low DAS28-CRP due to previous IFX treatment decreased further with continued CT-P13 therapy. As in naïve patients, patients who switched from other bDMARDs, mainly for medical reasons (n = 102), responded similarly to CT-P13. CT-P13 in this PMS and IFX in a previous PMS had similar adverse reaction profiles, although the incidence rate in naïve patients in this current PMS was lower due to earlier initiation of CT-P13 therapy. CONCLUSIONS CT-P13 showed excellent effectiveness as first-line therapy, no clinical difficulties in switching from IFX, and clinical improvement in patients who failed other bDMARDs. CT-P13 could be a cost-effective alternative to IFX in the treatment of rheumatoid arthritis.
Collapse
Affiliation(s)
- Tsutomu Takeuchi
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Kiyohiro Nishikawa
- Quality & Pharmacovigilance Division, Pharmaceuticals Group, Nippon Kayaku Co., Ltd., Tokyo, Japan.,Asajes Ventures,Tokyo, Japan
| | - Fumika Yamada
- Quality & Pharmacovigilance Division, Pharmaceuticals Group, Nippon Kayaku Co., Ltd., Tokyo, Japan
| | - Shiro Ohshima
- Department of Rheumatology and Allergology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan
| | - Makoto Inoue
- Department of Rheumatology, Inoue Hospital, Takasaki, Gunma, Japan
| | - Yutaka Yoshioka
- Department of Rheumatology, Handa City Hospital, Handa, Aichi, Japan
| | | |
Collapse
|
8
|
Suzuki M, Kojima T, Takahashi N, Asai S, Terabe K, Kaneko A, Hirano Y, Hanabayashi M, Oguchi T, Takagi H, Kanayama Y, Yabe Y, Funahashi K, Fujibayashi T, Tsuboi S, Ito T, Yoshioka Y, Ishikawa H, Sobue Y, Nishiume T, Yokota Y, Ishiguro N. Higher doses of methotrexate associated with discontinuation of oral glucocorticoids after initiation of biological DMARDs: A retrospective observational study based on data from a Japanese multicenter registry study. Mod Rheumatol 2021; 31:796-802. [PMID: 33492191 DOI: 10.1080/14397595.2021.1879428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
OBJECTIVE Glucocorticoids are important drugs used to treat rheumatoid arthritis. We recommend glucocorticoid discontinuation as soon as possible given the associated side-effects, but many patients continue to take oral glucocorticoids long-term. The present study aimed to explore factors associated with glucocorticoid discontinuation at 52 weeks after initiating biological disease-modifying antirheumatic drugs (bDMARDs). METHODS Subjects were 564 patients from a Japanese multicenter registry who were administered glucocorticoids and methotrexate (MTX) followed by initiation of the first bDMARD. We examined the status of oral glucocorticoid use at 52 weeks after initiating the first bDMARD. RESULTS By 52 weeks after bDMARD initiation, 164 patients (29.1%) discontinued glucocorticoids. Multivariable analysis identified age, MTX dose, and glucocorticoid dose as factors independently associated with glucocorticoid discontinuation. After adjusting for baseline characteristics using propensity score matching, among patient groups administered MTX ≤ 8 mg/week and MTX > 8 mg/week, 105 pairs remained. A significantly higher rate of glucocorticoid discontinuation (41.0%) was noted for patients administered MTX > 8 mg/week. CONCLUSION Our findings suggest that glucocorticoids may be discontinued after initiating bDMARDs. Moreover, higher MTX doses (>8 mg/week) at the time of bDMARD initiation were associated with glucocorticoid discontinuation among patients treated with bDMARDs.
Collapse
Affiliation(s)
- Mochihito Suzuki
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Toshihisa Kojima
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Nobunori Takahashi
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Shuji Asai
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Kenya Terabe
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Atsushi Kaneko
- Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Aichi, Japan
| | - Yuji Hirano
- Department of Rheumatology, Toyohashi Municipal Hospital, Aichi, Japan
| | | | - Takeshi Oguchi
- Department of Orthopedic Surgery and Rheumatology, Anjo Kosei Hospital, Aichi, Japan
| | - Hideki Takagi
- Department of Orthopedic Surgery, Nagoya Central Hospital, Aichi, Japan
| | | | - Yuichiro Yabe
- Department of Rheumatology, Japan Community Healthcare Organization Tokyo Shinjuku Medical Center, Tokyo, Japan
| | - Koji Funahashi
- Department of Orthopedic Surgery, Kariya-Toyota General Hospital, Aichi, Japan
| | - Takayoshi Fujibayashi
- Department of Orthopedic Surgery and Rheumatology, Konan Kosei Hospital, Aichi, Japan
| | - Seiji Tsuboi
- Department of Orthopedic Surgery, Shizuoka Kosei Hospital, Shizuoka, Japan
| | | | - Yutaka Yoshioka
- Department of Orthopedic Surgery, Handa Municipal Hospital, Aichi, Japan
| | - Hisato Ishikawa
- Department of Rheumatology, Japanese Red Cross, Nagoya Daiichi Hospital, Aichi, Japan
| | - Yasumori Sobue
- Department of Rheumatology, Japanese Red Cross, Nagoya Daiichi Hospital, Aichi, Japan
| | - Tsuyoshi Nishiume
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Yutaka Yokota
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Aichi, Japan
| | | |
Collapse
|
9
|
Takahashi N, Asai S, Kobayakawa T, Kaneko A, Watanabe T, Kato T, Nishiume T, Ishikawa H, Yoshioka Y, Kanayama Y, Watanabe T, Hirano Y, Hanabayashi M, Yabe Y, Yokota Y, Suzuki M, Sobue Y, Terabe K, Ishiguro N, Kojima T. Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry. Sci Rep 2020; 10:21907. [PMID: 33318522 PMCID: PMC7736589 DOI: 10.1038/s41598-020-78925-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Accepted: 12/02/2020] [Indexed: 12/19/2022] Open
Abstract
This study aimed to evaluate the short-term effectiveness and safety profiles of baricitinib and explore factors associated with improved short-term effectiveness in patients with rheumatoid arthritis (RA) in clinical settings. A total of 113 consecutive RA patients who had been treated with baricitinib were registered in a Japanese multicenter registry and followed for at least 24 weeks. Mean age was 66.1 years, mean RA disease duration was 14.0 years, 71.1% had a history of use of biologics or JAK inhibitors (targeted DMARDs), and 48.3% and 40.0% were receiving concomitant methotrexate and oral prednisone, respectively. Mean DAS28-CRP significantly decreased from 3.55 at baseline to 2.32 at 24 weeks. At 24 weeks, 68.2% and 64.1% of patients achieved low disease activity (LDA) and moderate or good response, respectively. Multivariate logistic regression analysis revealed that no previous targeted DMARD use and lower DAS28-CRP score at baseline were independently associated with achievement of LDA at 24 weeks. While the effectiveness of baricitinib was similar regardless of whether patients had a history of only one or multiple targeted DMARDs use, patients with previous use of non-TNF inhibitors or JAK inhibitors showed lower rates of improvement in DAS28-CRP. The overall retention rate for baricitinib was 86.5% at 24 weeks, as estimated by Kaplan-Meier analysis. The discontinuation rate due to adverse events was 6.5% at 24 weeks. Baricitinib significantly improved RA disease activity in clinical practice. Baricitinib was significantly more effective when used as a first-line targeted DMARDs.
Collapse
Affiliation(s)
- Nobunori Takahashi
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Aichi, Nagoya, 466-8550, Japan.
| | - Shuji Asai
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Aichi, Nagoya, 466-8550, Japan
| | - Tomonori Kobayakawa
- Kobayakawa Orthopedic and Rheumatologic Clinic, 1969 Kuno, Fukuroi, Shizuoka, Japan
| | - Atsushi Kaneko
- Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, 4-1-1 Sanno-maru, Naka-ku, Nagoya, Aichi, Japan
| | - Tatsuo Watanabe
- Department of Orthopedic Surgery, Daido Hospital, 9 Shiramizu-cho, Minami-ku, Nagoya, Aichi, Japan
| | - Takefumi Kato
- Kato Orthopedic Clinic, 8-4 Minami-myoudaiji-cho, Okazaki, Japan
| | - Tsuyoshi Nishiume
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Aichi, Nagoya, 466-8550, Japan
| | - Hisato Ishikawa
- Department of Rheumatology, Japanese Red Cross Nagoya Daiichi Hospital, 35 Michisita-cho, Nakamura-ku, Nagoya, Aichi, Japan
| | - Yutaka Yoshioka
- Department of Rheumatology, Handa City Hospital, 2-29 Toyo-cho, Handa, Aichi, Japan
| | - Yasuhide Kanayama
- Department of Orthopedic Surgery, Toyota Kosei Hospital, 500-1 Ibohara, Josui-cho, Toyota, Japan
| | - Tsuyoshi Watanabe
- Department of Orthopedic Surgery, National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu, Aichi, Japan
| | - Yuji Hirano
- Department of Rheumatology, Toyohashi Municipal Hospital, 50 Hakken-nishi, Aotake-cho, Toyohashi, Japan
| | - Masahiro Hanabayashi
- Department of Orthopedic Surgery, Ichinomiya Municipal Hospital, 2-2-22 Bunkyo, Ichinomiya, Japan
| | - Yuichiro Yabe
- Department of Rheumatology, Tokyo Shinjuku Medical Center, 5-1 Tsukudo-cho, Shinjuku-ku, Tokyo, Japan
| | - Yutaka Yokota
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Aichi, Nagoya, 466-8550, Japan
| | - Mochihito Suzuki
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Aichi, Nagoya, 466-8550, Japan
| | - Yasumori Sobue
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Aichi, Nagoya, 466-8550, Japan
| | - Kenya Terabe
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Aichi, Nagoya, 466-8550, Japan
| | - Naoki Ishiguro
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Aichi, Nagoya, 466-8550, Japan
| | - Toshihisa Kojima
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Aichi, Nagoya, 466-8550, Japan
| |
Collapse
|
10
|
Ito M, Takase Y, Sasamura K, Kotsuma T, Ooshima Y, Minami Y, Suzuki J, Tanaka E, Oguchi M, Okuda T, Suzuki K, Yoshioka Y. Comparison of Physician-Recorded Toxicities and Patient-Reported Outcomes Among 5 Different Radiotherapy Methods for Prostate Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Asai S, Takahashi N, Hayashi M, Hanabayashi M, Kanayama Y, Takemoto T, Yabe Y, Shioura T, Ishikawa H, Yoshioka Y, Kato T, Hirano Y, Fujibayashi T, Hattori Y, Kobayakawa T, Ando M, Kuwatsuka Y, Matsumoto T, Asai N, Sobue Y, Nishiume T, Suzuki M, Ishiguro N, Kojima T. Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab. Joint Bone Spine 2020; 87:596-602. [PMID: 32534200 DOI: 10.1016/j.jbspin.2020.06.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Accepted: 06/05/2020] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To investigate predictors of disease flare after methotrexate discontinuation in Japanese rheumatoid arthritis (RA) patients with sustained low disease activity undergoing tocilizumab plus methotrexate combination therapy. METHODS Participants of this multicenter, open-label, uncontrolled, prospective study were RA patients maintaining low disease activity (Clinical Disease Activity Index [CDAI]≤10) for≥12weeks with tocilizumab plus methotrexate. Methotrexate was discontinued after 12weeks of biweekly administration while continuing tocilizumab therapy. Disease flare was defined as either a CDAI score>10 or intervention with rescue treatments for any reason even if the CDAI score was≤10. The impact of baseline characteristics on disease flare at week 64 (52weeks after methotrexate discontinuation) was assessed with logistic regression models. RESULTS Efficacy analyses were performed in 49 patients, of whom 15 had a disease flare by week 64. The proportion (95% confidence interval [CI]) of patients who maintained low disease activity without a flare at week 64 was 69.4% (54.6-81.8%). The dosing interval of tocilizumab was longer than that described on the drug label in Japan (i.e., intravenously every 4weeks, or subcutaneously every 2weeks) in 27% and 6% of patients with and without a flare, respectively. Multivariate analysis revealed that male sex (odds ratio [OR]: 18.00, 95% CI: 2.80-115.56) and extended dosing interval of tocilizumab (OR: 12.00, 95% CI: 1.72-83.80) were independent predictors of disease flare. CONCLUSION Male patients and those receiving tocilizumab at an extended dosing interval are at high risk of disease flare after discontinuation of concomitant methotrexate. TRIAL REGISTRATION NUMBER jRCTs041180071, UMIN000021247.
Collapse
Affiliation(s)
- Shuji Asai
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Nobunori Takahashi
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Masatoshi Hayashi
- Department of Rheumatology, Nagano Red Cross Hospital, 5-22-1 Wakasato, Nagano, Nagano 380-8582, Japan
| | - Masahiro Hanabayashi
- Department of Rheumatology, Ichinomiya Municipal Hospital, 2-2-22 Bunkyo, Ichinomiya, Aichi 491-8558, Japan
| | - Yasuhide Kanayama
- Department of Rheumatology, Toyota Kosei Hospital, 500-1 Ibobara, Josui-cho, Toyota, Aichi 470-0396, Japan
| | - Toki Takemoto
- Department of Orthopedic Surgery, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Aichi 446-8602, Japan
| | - Yuichiro Yabe
- Department of Rheumatology, Tokyo Shinjuku Medical Center, 5-1 Tsukudo-cho, Shinjuku-ku, Tokyo 162-8543, Japan
| | - Tomone Shioura
- Department of Rheumatology, Shizuoka Kosei Hospital, 23 Kitaban-cho, Aoi-ku, Shizuoka, Shizuoka 420-8623, Japan
| | - Hisato Ishikawa
- Department of Rheumatology, Japanese Red Cross Nagoya Daiichi Hospital, 3-35 Michishita-cho, Nakamura-ku, Nagoya, Aichi 453-8511, Japan
| | - Yutaka Yoshioka
- Department of Rheumatology, Handa Municipal Hospital, 2-29 Toyo-cho, Handa, Aichi 475-8599, Japan
| | - Takefumi Kato
- Kato Orthopedic Clinic, 8-4 Minamimyodaiji-cho, Okazaki, Aichi 444-0852, Japan
| | - Yuji Hirano
- Department of Rheumatology, Toyohashi Municipal Hospital, 50 Aotake-cho, Toyohashi, Aichi 441-8570, Japan
| | - Takayoshi Fujibayashi
- Department of Orthopedic Surgery, Konan Kosei Hospital, 137 Omatsubara, Takaya-cho, Konan, Aichi 483-8704, Japan
| | - Yosuke Hattori
- Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi 460-0001, Japan
| | - Tomonori Kobayakawa
- Department of Rheumatology, Chutoen General Medical Center, 1-1 Shobugaike, Kakegawa, Shizuoka 436-8555, Japan
| | - Masahiko Ando
- Department of Advanced Medicine, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Yachiyo Kuwatsuka
- Department of Advanced Medicine, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Takuya Matsumoto
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan; Department of Rheumatology, Shizuoka Kosei Hospital, 23 Kitaban-cho, Aoi-ku, Shizuoka, Shizuoka 420-8623, Japan
| | - Nobuyuki Asai
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan; Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi 460-0001, Japan
| | - Yasumori Sobue
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Tsuyoshi Nishiume
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Mochihito Suzuki
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Naoki Ishiguro
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
| | - Toshihisa Kojima
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
| |
Collapse
|
12
|
Yoshikawa T, Haruki N, Yoshimura C, Yoshioka Y, Ando SI. The relationships between hypoxia and oxidative stress as well as anti-oxidant activity in patients with severe sleep disordered breathing. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.1216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Yamashita T, Kamada H, Kanasaki S, Nagano K, Inoue M, Higashisaka K, Yoshioka Y, Tsutsumi Y, Tsunoda S. Ephrin type-A receptor 2 on tumor-derived exosomes enhances angiogenesis through the activation of MAPK signaling. Pharmazie 2019; 74:614-619. [PMID: 31685088 DOI: 10.1691/ph.2019.9474] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Exosomes are potent players in the development of metastases and they play an important role in cancer angiogenesis and exacerbation. However, it is unclear how proteins on exosomes affect development of blood vessel networks. In this study, we focused on relationships between membrane proteins on exosomes and angiogenesis using human umbilical vein endothelial cells (HUVEC). Lung tumor cell-derived exosomes induced tube formation and growth of endothelial cells in vitro in a dose-dependent manner involving MAPK activation, but this was not seen in normal lung epithelial cells. Ephrin type-A receptor 2 (EphA2) was identified by proteomic analysis and an inhibition assays showed it is a major MAPK activator on exosomes. Thus EphA2 on exosomes participates in angiogenesis as a ligand of the ephrin signaling pathway. These results support the development of novel therapeutic strategies such as blockade of remote cancer communications through exosomes.
Collapse
|
14
|
Taguchi S, Yoshioka Y, Mishima Y, Nishimura N, Yokoyama M, Takeuchi K, Terui Y, Oguchi M. Assessment of Late Toxicities of Liver and Kidney after Definitive Radiotherapy for Gastric MALT Lymphoma. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Yoshioka Y, Hayashi S, Hamada A, Toratani S, Okamoto T. Metastasis of carcinoma ex pleomorphic adenoma to the brain without previous metastasis to the lungs or bones: a case report. Br J Oral Maxillofac Surg 2019; 57:926-928. [PMID: 31405601 DOI: 10.1016/j.bjoms.2019.07.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Accepted: 07/19/2019] [Indexed: 11/18/2022]
Abstract
Carcinoma ex pleomorphic adenoma is a rare type of cancer of the salivary gland that involves the malignant transformation of a primary or recurrent pleomorphic adenoma, which often metastasises to the lungs or bones, or both. To the best of our knowledge, however, nobody has reported a distant metastasis of this lesion to the brain without such previous metastasis. We report a case in a 64-year-old man.
Collapse
Affiliation(s)
- Y Yoshioka
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Science, Graduate Institute of Biomedical and Health Science, Hiroshima University.
| | - S Hayashi
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Science, Graduate Institute of Biomedical and Health Science, Hiroshima University
| | - A Hamada
- Oral and Maxillofacial Surgery, Hiroshima University Hospital
| | - S Toratani
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Science, Graduate Institute of Biomedical and Health Science, Hiroshima University
| | - T Okamoto
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Science, Graduate Institute of Biomedical and Health Science, Hiroshima University; Oral and Maxillofacial Surgery, Hiroshima University Hospital
| |
Collapse
|
16
|
Asai S, Hayashi M, Hanabayashi M, Kanayama Y, Takemoto T, Yabe Y, Shioura T, Ishikawa H, Yoshioka Y, Kato T, Hirano Y, Fujibayashi T, Hattori Y, Kobayakawa T, Ando M, Kuwatsuka Y, Takahashi N, Matsumoto T, Asai N, Sobue Y, Nishiume T, Suzuki M, Ishiguro N, Kojima T. Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study. Mod Rheumatol 2019; 30:434-441. [PMID: 31390271 DOI: 10.1080/14397595.2019.1641934] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Objectives: To evaluate the efficacy and safety of methotrexate (MTX) discontinuation in Japanese rheumatoid arthritis (RA) patients with sustained low disease activity undergoing combination therapy with tocilizumab (TCZ) plus MTX.Methods: This multicenter, open-label, uncontrolled, prospective study included RA patients maintaining low disease activity (Clinical Disease Activity Index (CDAI) ≤10) for ≥12 weeks with TCZ plus MTX. Methotrexate was discontinued following 12 weeks of biweekly administration while continuing TCZ therapy. The primary endpoint was the proportion of patients maintaining low disease activity with no flare at week 36.Results: A total of 49 patients completed 36 weeks of therapy. The proportion of patients maintaining low disease activity at week 36 was 75.5%. The lower limit of the 95% confidence interval exceeded the assumed threshold response rate of 60%, demonstrating the clinical feasibility of MTX discontinuation. The prevalence of gastroesophageal reflux disease, defined as a Frequency Scale for Symptoms of Gastroesophageal reflux disease score ≥8, significantly decreased from week 0 to 12 (27.1-18.4%; p= .025).Conclusion: Discontinuation of concomitant MTX is clinically feasible for maintaining low disease activity, and may be beneficial from the perspective of reducing gastrointestinal symptoms in Japanese RA patients treated with TCZ. Trial registration number: UMIN000021247.
Collapse
Affiliation(s)
- Shuji Asai
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Masatoshi Hayashi
- Department of Rheumatology, Nagano Red Cross Hospital, Nagano, Japan
| | | | | | - Toki Takemoto
- Department of Orthopedic Surgery, Anjo Kosei Hospital, Anjo, Japan
| | - Yuichiro Yabe
- Department of Rheumatology, Tokyo Shinjuku Medical Center, Tokyo, Japan
| | - Tomone Shioura
- Department of Rheumatology, Shizuoka Kosei Hospital, Shizuoka, Japan
| | - Hisato Ishikawa
- Department of Rheumatology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan
| | - Yutaka Yoshioka
- Department of Rheumatology, Handa Municipal Hospital, Handa, Japan
| | | | - Yuji Hirano
- Department of Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
| | | | - Yosuke Hattori
- Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan
| | | | - Masahiko Ando
- Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan
| | - Yachiyo Kuwatsuka
- Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan
| | - Nobunori Takahashi
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Takuya Matsumoto
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Nobuyuki Asai
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yasumori Sobue
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Tsuyoshi Nishiume
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Mochihito Suzuki
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Naoki Ishiguro
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Toshihisa Kojima
- Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
17
|
Toratani S, Ogawa I, Sasahara H, Yoshioka Y, Kanda T, Tani R, Okamoto T. Pathological factors involved in local failure in squamous cell carcinoma of the oral cavity: retrospective study and proposal of a new clinical classification. Int J Oral Maxillofac Surg 2019; 48:143-151. [DOI: 10.1016/j.ijom.2018.07.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2017] [Revised: 04/03/2018] [Accepted: 07/06/2018] [Indexed: 01/28/2023]
|
18
|
Harada A, Sumi M, Toshiyasu T, Yoshioka Y, Takazawa Y, Ae K, Matsumoto S, Oguchi M. Palliative Radiation Therapy for Spinal Metastasis from Myxoid Liposarcoma. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Isoda K, Daibo T, Yushina K, Yoshioka Y, Tsutsumi Y, Akimoto Y, Kawakami H, Taira Y, Taira I, Yanoshita R, Nishimura T, Ishida I. Hepatotoxicity, nephrotoxicity, and drug/chemical interaction toxicity of platinum nanoparticles in mice. Pharmazie 2018; 72:10-16. [PMID: 29441891 DOI: 10.1691/ph.2017.6758] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Nanomaterials are frequently used in microelectronics, cosmetics, and sunscreens. Platinum reagents are commonly used in disease diagnosis, cosmetics, and the food industry. Although research into the development of nanomaterialbased drug delivery systems has yielded promising results, the toxicity of these materials is not fully understood. We investigated the toxicity and drug interactions of 1- and 8-nm diameter platinum nanoparticles (nPt1 and nPt8, respectively) in mice. Acute hepato-renal toxicity of intravenously administered platinum nanoparticles was evaluated biochemically and histologically. Dose-dependent increases in serum markers of hepato-renal function (serum aminotransferases and blood urea nitrogen) were observed following administration of nPt1, whereas nPt8 had no effect, even at 20 mg/kg. Moreover, nPt1 induced interleukin (IL)-6 and IL-1β production 3 and 6 hours after administration. The effect of nPts on drug-induced toxicity was evaluated in mice injected intraperitoneally with carbon tetrachloride or cisplatin, with or without intravenous administration of platinum nanoparticles. All treatments in the absence of nanoparticles were non-lethal and resulted in moderate toxicity. However, exacerbated toxicity was observed in mice injected with carbon tetrachloride or cisplatin together with nPt1, but not in mice co-injected with nPt8. We found that nPt1 cause hepato-renal damage, and the effect is enhanced by chemical inducers of hepatotoxicity and nephrotoxicity. This is the first report demonstrating that nPt1 not only are hepatotoxic and nephrotoxic but also exacerbate drug toxicity. These findings will be useful for future nanotechnology and nanoscience research.
Collapse
|
20
|
Yoshioka Y, Yamachika E, Nakanishi M, Ninomiya T, Nakatsuji K, Kobayashi Y, Fujii T, Iida S. Cathepsin K inhibitor causes changes in crystallinity and crystal structure of newly-formed mandibular bone in rats. Br J Oral Maxillofac Surg 2018; 56:732-738. [PMID: 30131193 DOI: 10.1016/j.bjoms.2018.08.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Accepted: 08/03/2018] [Indexed: 11/16/2022]
Abstract
Cathepsin K inhibitors are new drugs with the potential for the treatment of osteoporosis because they sustain bony remodelling better than bone resorption inhibitors such as bisphosphonates. The treatment of osteoporosis with inhibitors of bony resorption is associated with osteonecrosis of the jaw, as the deterioration in bony quality that they induce is thought to be one of its causes. The quality of bone is delineated by structural and material characteristics (which include the degree and quality of mineralisation, and depends on the content of proteoglycan and the structural integrity of the bony collagen).1,2 Animal and clinical studies have shown that cathepsin K inhibitors improve the mineral density and structural characteristics of bone, but their effect on the rest remains unknown. We therefore hypothesised that these inhibitors will affect the material characteristics of newly-formed mandibular bone. To verify our hypothesis, we used Raman microspectroscopy to examine such bone in rats that were given a cathepsin K inhibitor, and found unusual crystallinity and an increased substitution of carbonate (CO32-) in its crystal structure.
Collapse
Affiliation(s)
- Y Yoshioka
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama City 700-8558, Japan
| | - E Yamachika
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City 700-8558, Japan.
| | - M Nakanishi
- Department of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University, 1-1-1 Tsushima-Naka, Kita-ku, Okayama City 700-8530, Japan
| | - T Ninomiya
- Division of Hard Tissue Research, Institute for Oral Science, Matsumoto Dental University, 1780 Gobara Hirooka, Shiojiri, Nagano 399-0781, Japan
| | - K Nakatsuji
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama City 700-8558, Japan
| | - Y Kobayashi
- Division of Hard Tissue Research, Institute for Oral Science, Matsumoto Dental University, 1780 Gobara Hirooka, Shiojiri, Nagano 399-0781, Japan
| | - T Fujii
- Department of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University, 1-1-1 Tsushima-Naka, Kita-ku, Okayama City 700-8530, Japan
| | - S Iida
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama City 700-8558, Japan
| |
Collapse
|
21
|
Yoshioka Y, Yamachika E, Nakanishi M, Ninomiya T, Nakatsuji K, Matsubara M, Moritani N, Kobayashi Y, Fujii T, Iida S. Molecular alterations of newly formed mandibular bone caused by zoledronate. Int J Oral Maxillofac Surg 2018; 47:1206-1213. [PMID: 29550280 DOI: 10.1016/j.ijom.2018.02.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Revised: 12/07/2017] [Accepted: 02/06/2018] [Indexed: 12/21/2022]
Abstract
Bone quality is defined by structural and material characteristics. Most studies on the mandible have focused on the analysis of structural characteristics, with insufficient investigation of material characteristics. This study tested whether zoledronate affects the material characteristics of newly formed mandibular bone. Thirty-six female Wistar rats were assigned to three groups: sham-ovariectomized rats (SHAM, n=12), ovariectomized rats (OVX, n=12), and ovariectomized rats treated with zoledronate (ZOL, n=12). The left side of the mandibular ramus of all rats was drilled bicortically. Twenty-eight days after surgery, all surviving rats were euthanized and all mandibles were removed. Raman microspectroscopy was performed, and five spectra per specimen of newly formed mandibular bone were analysed. Compared with OVX rats, the mineral/matrix ratio in ZOL rats was significantly increased (5.43±1.88 vs. 7.86±2.05), while crystallinity (0.055±0.002 vs. 0.050±0.002), relative proteoglycan content (0.43±0.10 vs. 0.31±0.05), and collagen structural integrity (1.16±0.21 vs. 0.72±0.06) were significantly decreased. These changes in material characteristics may explain why rats that received zoledronate exhibited peculiar biological phenomena such as bisphosphonate-related osteonecrosis of the jaw.
Collapse
Affiliation(s)
- Y Yoshioka
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
| | - E Yamachika
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Hospital, Okayama City, Japan.
| | - M Nakanishi
- Department of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University, Okayama City, Japan
| | - T Ninomiya
- Division of Hard Tissue Research, Institute for Oral Science, Matsumoto Dental University, Shiojiri, Nagano, Japan
| | - K Nakatsuji
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
| | - M Matsubara
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
| | - N Moritani
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
| | - Y Kobayashi
- Division of Hard Tissue Research, Institute for Oral Science, Matsumoto Dental University, Shiojiri, Nagano, Japan
| | - T Fujii
- Department of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University, Okayama City, Japan
| | - S Iida
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
| |
Collapse
|
22
|
Yoshioka Y, Yamamoto U, Tsuda H, Handa S, Yoshimura C, Tokunoh T, Nishizaka M, Ando SI. The factors that affect to the better compliance of mandibular advancement device when compared with continuous positive airway pressure in the patients with moderate to severe sleep apnea syndrome. Sleep Med 2017. [DOI: 10.1016/j.sleep.2017.11.1055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
23
|
Murata K, Akiyama R, Noro I, Nishio A, Nakagawa S, Yoshioka Y, Deguchi T, Matsuda H, Ishida Y. Search for effective plant materials for Alzheimer's disease. Am J Transl Res 2017. [DOI: 10.1055/s-0037-1608412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- K Murata
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - R Akiyama
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - I Noro
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - A Nishio
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - S Nakagawa
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | | | - T Deguchi
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - H Matsuda
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - Y Ishida
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| |
Collapse
|
24
|
Fukuchi H, Okawa T, Yamamoto T, Kato S, Nakajima N, Yoshioka Y. Detection of recognition from ambiguous visual information using FMRI. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Amano M, Namiki T, Yoshioka Y, Arima Y, Kato K, Nojima K, Hanafusa T, Tokoro S, Miura K, Yokozeki H. Necrotizing fasciitis of the lower leg caused by Escherichia coli, and an association with pyogenic spondylitis. Clin Exp Dermatol 2017; 42:918-920. [PMID: 28925014 DOI: 10.1111/ced.13209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/04/2017] [Indexed: 11/30/2022]
Affiliation(s)
- M Amano
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - T Namiki
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - Y Yoshioka
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - Y Arima
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - K Kato
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - K Nojima
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - T Hanafusa
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - S Tokoro
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - K Miura
- Department of Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - H Yokozeki
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| |
Collapse
|
26
|
Moritani N, Yoshioka Y, Yamachika E, Matsui Y, Tabata M, Ikeda A, Uemura A, Nakatsuji K, Matsumura T, Iida S. A familial case of cleidocranial dysplasia with a frameshift mutation in the Runt-related transcription factor 2 gene. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
27
|
Kawashima A, Isohashi F, Mabuchi S, Okubo H, Tamari K, Seo Y, Suzuki O, Yoshioka Y, Kimura T, Ogawa K. Early Outcomes and Dose-Volume Analysis for Patients With Cervical Cancer Treated With Computed Tomography-Based Treatment Planning in Brachytherapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
28
|
Isohashi F, Mabuchi S, Yoshioka Y, Tamari K, Suzuki O, Koizumi M, Kawashima A, Okubo H, Kimura T, Ogawa K. Postoperative Whole-Pelvic Intensity Modulated Radiation Therapy in Surgically Treated Cervical Cancer Patients With Adverse Risk Factors. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
29
|
Ono E, Murota H, Mori Y, Yoshioka Y, Katamaya I. 055 Metabolomics analysis of sweat derived from atopic dermatitis by use of nuclear magnetic resonance. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Matsumoto T, Takahashi N, Kojima T, Yoshioka Y, Ishikawa J, Furukawa K, Ono K, Sawada M, Ishiguro N, Yamamoto A. Soluble Siglec-9 suppresses arthritis in a collagen-induced arthritis mouse model and inhibits M1 activation of RAW264.7 macrophages. Arthritis Res Ther 2016; 18:133. [PMID: 27267914 PMCID: PMC4897938 DOI: 10.1186/s13075-016-1035-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Accepted: 05/27/2016] [Indexed: 11/10/2022] Open
Abstract
Background The aim of this study was to assess the effects of soluble sialic acid-binding immunoglobulin-type lectin (sSiglec)-9 on joint inflammation and destruction in a murine collagen-induced arthritis (CIA) model and in monolayer cultures of murine macrophages (RAW264.7 cells and peritoneal macrophages) and fibroblast-like synoviocytes (FLS) derived from patients with rheumatoid arthritis. Methods DBA/1J mice were immunized with type II collagen. Effects of sSiglec-9 were evaluated using a physiologic arthritis score, histological analysis, serum tumor necrosis factor (TNF)-α concentration, and the proportion of forkhead box P3 (Foxp3)-positive regulatory T (Treg) cells. In vivo biofluorescence imaging was used to assess the distribution of sSiglec-9. Levels of M1 (TNF-α, interleukin [IL]-6, and inducible nitric oxide synthase) and M2 (CD206, Arginase-1, and IL-10) macrophage markers and phosphorylation of intracellular signaling molecules were examined in macrophages, and levels of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 were examined in FLS. Results sSiglec-9 significantly suppressed the clinical and histological incidence and severity of arthritis. The proportion of Foxp3-positive Treg cells significantly improved and serum TNF-α concentration decreased in vivo. Although sSiglec-9 reduced the expression of M1 markers in macrophages, it did not affect the expression of M2 markers and MMPs in FLS. Nuclear factor (NF)-kB p65 phosphorylation was attenuated by sSiglec-9, and chemical blockade of the NF-kB pathway reduced M1 marker expression in RAW264.7 cells. Conclusions In this study, we have demonstrated the therapeutic effects of sSiglec-9 in a murine CIA model. The mechanism underlying these effects involves the suppression of M1 proinflammatory macrophages by inhibiting the NF-kB pathway. sSiglec-9 may provide a novel therapeutic option for patients with rheumatoid arthritis refractory to currently available drugs.
Collapse
Affiliation(s)
- Takuya Matsumoto
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Nobunori Takahashi
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
| | - Toshihisa Kojima
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Yutaka Yoshioka
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Jun Ishikawa
- Department of Oral and Maxillofacial Surgery/Protective Care for Masticatory Disorders, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Koichi Furukawa
- Department of Biochemistry II, Nagoya University Graduate School of Medicine, Nagoya, 466-0065, Japan
| | - Kenji Ono
- Research Institute of Environmental Medicine, Nagoya University, Nagoya, 464-8601, Japan
| | - Makoto Sawada
- Research Institute of Environmental Medicine, Nagoya University, Nagoya, 464-8601, Japan
| | - Naoki Ishiguro
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Akihito Yamamoto
- Department of Oral and Maxillofacial Surgery/Protective Care for Masticatory Disorders, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| |
Collapse
|
31
|
Hirai T, Yoshioka Y, Takahashi H, Handa T, Izumi N, Mori T, Uemura E, Nishijima N, Sagami K, Yamaguchi M, Eto S, Nagano K, Kamada H, Tsunoda S, Ishii KJ, Higashisaka K, Tsutsumi Y. High-dose cutaneous exposure to mite allergen induces IgG-mediated protection against anaphylaxis. Clin Exp Allergy 2016; 46:992-1003. [DOI: 10.1111/cea.12722] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Revised: 01/18/2016] [Accepted: 02/07/2016] [Indexed: 11/30/2022]
Affiliation(s)
- T. Hirai
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - Y. Yoshioka
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
- Vaccine Creation Project; BIKEN Innovative Vaccine Research Alliance Laboratories; Research Institute for Microbial Diseases; Osaka University; Osaka Japan
- BIKEN Center for Innovative Vaccine Research and Development; The Research Foundation for Microbial Diseases of Osaka University; Osaka Japan
| | - H. Takahashi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
- Vaccine Creation Project; BIKEN Innovative Vaccine Research Alliance Laboratories; Research Institute for Microbial Diseases; Osaka University; Osaka Japan
| | - T. Handa
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - N. Izumi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - T. Mori
- Laboratory of Innovative Antibody Engineering and Design; Center for Drug Innovation and Screening; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
| | - E. Uemura
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - N. Nishijima
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - K. Sagami
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - M. Yamaguchi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - S. Eto
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - K. Nagano
- Laboratory of Biopharmaceutical Research; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
| | - H. Kamada
- Laboratory of Biopharmaceutical Research; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- The Center for Advanced Medical Engineering and Informatics; Osaka University; Osaka Japan
| | - S. Tsunoda
- Laboratory of Biopharmaceutical Research; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- The Center for Advanced Medical Engineering and Informatics; Osaka University; Osaka Japan
| | - K. J. Ishii
- Laboratory of Adjuvant Innovation; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- Laboratory of Vaccine Science; Immunology Frontier Research Center; World Premier International Research Center; Osaka University; Osaka Japan
| | - K. Higashisaka
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - Y. Tsutsumi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
- Laboratory of Innovative Antibody Engineering and Design; Center for Drug Innovation and Screening; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- The Center for Advanced Medical Engineering and Informatics; Osaka University; Osaka Japan
| |
Collapse
|
32
|
Kojima T, Takahashi N, Funahashi K, Asai S, Terabe K, Kaneko A, Hirano Y, Hayashi M, Miyake H, Oguchi T, Takagi H, Kanayama Y, Yabe Y, Watanabe T, Fujibayashi T, Shioura T, Ito T, Yoshioka Y, Ishikawa H, Asai N, Takemoto T, Kojima M, Ishiguro N. Improved safety of biologic therapy for rheumatoid arthritis over the 8-year period since implementation in Japan: long-term results from a multicenter observational cohort study. Clin Rheumatol 2016; 35:863-71. [DOI: 10.1007/s10067-016-3201-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Revised: 01/13/2016] [Accepted: 01/28/2016] [Indexed: 12/19/2022]
|
33
|
Ishikawa J, Takahashi N, Matsumoto T, Yoshioka Y, Yamamoto N, Nishikawa M, Hibi H, Ishigro N, Ueda M, Furukawa K, Yamamoto A. Factors secreted from dental pulp stem cells show multifaceted benefits for treating experimental rheumatoid arthritis. Bone 2016; 83:210-219. [PMID: 26603475 DOI: 10.1016/j.bone.2015.11.012] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Revised: 11/02/2015] [Accepted: 11/17/2015] [Indexed: 12/17/2022]
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial hyperplasia and chronic inflammation, which lead to the progressive destruction of cartilage and bone in the joints. Numerous studies have reported that administrations of various types of MSCs improve arthritis symptoms in animal models, by paracrine mechanisms. However, the therapeutic effects of the secreted factors alone, without the cell graft, have been uncertain. Here, we show that a single intravenous administration of serum-free conditioned medium (CM) from human deciduous dental pulp stem cells (SHED-CM) into anti-collagen type II antibody-induced arthritis (CAIA), a mouse model of rheumatoid arthritis (RA), markedly improved the arthritis symptoms and joint destruction. The therapeutic efficacy of SHED-CM was associated with an induction of anti-inflammatory M2 macrophages in the CAIA joints and the abrogation of RANKL expression. SHED-CM specifically depleted of an M2 macrophage inducer, the secreted ectodomain of sialic acid-binding Ig-like lectin-9 (ED-Siglec-9), exhibited a reduced ability to induce M2-related gene expression and attenuate CAIA. SHED-CM also inhibited the RANKL-induced osteoclastogenesis in vitro. Collectively, our findings suggest that SHED-CM provides multifaceted therapeutic effects for treating CAIA, including the ED-Siglec-9-dependent induction of M2 macrophage polarization and inhibition of osteoclastogenesis. Thus, SHED-CM may represent a novel anti-inflammatory and reparative therapy for RA.
Collapse
Affiliation(s)
- Jun Ishikawa
- Department of Oral and Maxillofacial Surgery, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - Nobunori Takahashi
- Orthopedic Surgery and Rheumatology, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - Takuya Matsumoto
- Orthopedic Surgery and Rheumatology, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - Yutaka Yoshioka
- Orthopedic Surgery and Rheumatology, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - Noriyuki Yamamoto
- Department of Oral and Maxillofacial Surgery, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - Masaya Nishikawa
- Department of Oral and Maxillofacial Surgery, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - Hideharu Hibi
- Department of Oral and Maxillofacial Surgery, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - Naoki Ishigro
- Orthopedic Surgery and Rheumatology, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - Minoru Ueda
- Department of Oral and Maxillofacial Surgery, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - Koichi Furukawa
- Biochemistry II of Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - Akihito Yamamoto
- Department of Oral and Maxillofacial Surgery, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
| |
Collapse
|
34
|
Asai S, Kojima T, Oguchi T, Kaneko A, Hirano Y, Yabe Y, Kanayama Y, Takahashi N, Funahashi K, Hanabayashi M, Hirabara S, Yoshioka Y, Takemoto T, Terabe K, Asai N, Ishiguro N. Effects of Concomitant Methotrexate on Large Joint Replacement in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors: A Multicenter Retrospective Cohort Study in Japan. Arthritis Care Res (Hoboken) 2015; 67:1363-70. [PMID: 25832554 DOI: 10.1002/acr.22596] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2014] [Revised: 02/19/2015] [Accepted: 03/24/2015] [Indexed: 11/06/2022]
Abstract
OBJECTIVE To determine the effects of concomitant methotrexate (MTX) on the incidence of large joint replacement resulting from the progression of large joint destruction in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF) inhibitors. METHODS A retrospective cohort study was performed using a multicenter registry. In total, 803 patients with RA who received etanercept or adalimumab were included. The first large joint replacement during treatment with etanercept or adalimumab was used as the outcome variable in predictive analyses. The cumulative incidence of large joint replacement was estimated using Kaplan-Meier curves, and the impact of concomitant MTX on the incidence of large joint replacement was assessed with Cox proportional hazards models. Propensity score matching was used to reduce selection bias. RESULTS Of all patients, 601 (75%) received concomitant MTX at a median dosage of 8 mg/week (interquartile range 6-8). A total of 49 patients (62 joints) underwent large joint replacement during treatment with etanercept or adalimumab. The incidence of large joint replacement for patients with concomitant MTX was significantly lower than that for patients without MTX (P < 0.001). Multivariate analysis revealed that concomitant MTX independently predicted large joint replacement (hazard ratio 0.36, 95% confidence interval 0.20-0.65). Additionally, propensity score-matched analysis demonstrated that patients with concomitant MTX had a significantly lower incidence of large joint replacement than those without concomitant MTX (P = 0.032). CONCLUSION Concomitant MTX reduces the incidence of large joint replacement in patients with RA treated with TNF inhibitors.
Collapse
Affiliation(s)
- Shuji Asai
- Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | | | | | - Yuji Hirano
- Toyohashi Municipal Hospital, Toyohashi, Japan
| | | | | | | | - Koji Funahashi
- Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | | | - Yutaka Yoshioka
- Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Toki Takemoto
- Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Kenya Terabe
- Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Nobuyuki Asai
- Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Naoki Ishiguro
- Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
35
|
Kojima T, Takahashi N, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Watanabe T, Hayashi M, Shioura T, Kanayama Y, Funahashi K, Asai S, Yoshioka Y, Terabe K, Takemoto T, Asai N, Ishiguro N. Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients. Clin Rheumatol 2015; 35:219-25. [PMID: 26631102 DOI: 10.1007/s10067-015-3135-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2015] [Revised: 10/13/2015] [Accepted: 11/26/2015] [Indexed: 01/22/2023]
Abstract
This study aimed to identify predictive factors for achieving low disease activity (LDA) in rheumatoid arthritis (RA) patients switching from tumor necrosis factor inhibitors (TNFis) to abatacept (ABT). Patients who were registered in the multicenter observational Tsurumai Biologics Communication Registry (TBCR) were enrolled in this study. Predictive factors for LDA achievement at each time point were determined by univariate and multivariate logistic regression analyses. The cutoffs of 28-point count Disease Activity Score (DAS28)-C-reactive protein (CRP) and ΔDAS28-CRP from baseline up to 24 weeks for LDA achievement at 52 weeks were explored using receiver operating characteristic (ROC) curves. Of 2771 RA patients registered until 2013, 76 with moderate or high disease activity were selected. Twenty-six percent of the patients achieved LDA. Multivariate analysis confirmed that DAS28-CRP at 12 weeks and ΔDAS28-CRP from baseline to 12 weeks were independent factors for LDA achievement at 52 weeks [odds ratio (OR) 0.26, 95% confident interval (CI) (0.12-0.56), OR 0.25, 95% CI (0.11-0.57), respectively]. The best cutoff values of DAS28-CRP at 12 weeks and ΔDAS28-CRP from baseline to 12 weeks for LDA at 52 weeks were 3.9 (sensitivity 0.85, specificity 0.78) and -0.97 (sensitivity 0.70, specificity 0.70), respectively. Seventy-one percent of patients who achieved both of these cutoff values at 12 weeks achieved LDA at 52 weeks. Our findings suggest that the clinical course up to 12 weeks is important for predicting long-term outcomes when switching from TNFis to ABT.
Collapse
Affiliation(s)
- Toshihisa Kojima
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
| | - Nobunori Takahashi
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Atsushi Kaneko
- Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, 4-1-1 Sanno-maru, Naka-ku, Nagoya, Aichi, Japan
| | - Daihei Kida
- Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, 4-1-1 Sanno-maru, Naka-ku, Nagoya, Aichi, Japan
| | - Yuji Hirano
- Department of Rheumatology, Toyohashi Municipal Hospital, 50 Hakken-nishi, Aotake-cho, Toyohashi, Japan
| | - Takayoshi Fujibayashi
- Department of Orthopedic Surgery, Konan Kosei Hospital, 137 Oomatsubara, Takaya-cho, Konan, Aichi, Japan
| | - Yuichiro Yabe
- Department of Rheumatology, JCHO Tokyo-Shinjyuku Medical Center, 5-1 Tsukudo-cho, Shinjuku-ku, Tokyo, Japan
| | - Hideki Takagi
- Department of Orthopedic Surgery, Nagoya Central Hospital, 3-7-7 Taiko, Nakamura-ku, Nagoya, Japan
| | - Takeshi Oguchi
- Department of Orthopedic Surgery, Anjo Kosei Hospital, 28 Higashihirokute, Anjo, Japan
| | - Hiroyuki Miyake
- Department of Orthopedic Surgery, Ichinomiya Municipal Hospital, 2-2-22, Bunkyo, Ichinomiya, Japan
| | - Takefumi Kato
- Kato Orthopedic Clinic, 8-4 Minami-myoudaiji-cho, Okazaki, Japan
| | - Tsuyoshi Watanabe
- Department of Orthopedic Surgery, Kariya-Toyota General Hospital, 5-15 Sumiyoshi-cho, Kariya, Japan
| | - Masatoshi Hayashi
- Department of Rheumatology, Nagano Red Cross Hospital, 5-22-1 Wakazato, Nagano, Japan
| | - Tomone Shioura
- Department of Orthopedic Surgery, Shizuoka Kosei Hospital, 23 Kitaban-cho, Aoi-ku, Shizuoka, Japan
| | - Yasuhide Kanayama
- Department of Orthopedic Surgery, Toyota Kosei Hospital, 500-1 Ibohara, Josui-cho, Toyota, Japan
| | - Koji Funahashi
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Shuji Asai
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Yutaka Yoshioka
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Kenya Terabe
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Toki Takemoto
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Nobuyuki Asai
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Naoki Ishiguro
- Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| |
Collapse
|
36
|
Kojima M, Kojima T, Suzuki S, Takahashi N, Funahashi K, Asai S, Yoshioka Y, Terabe K, Asai N, Takemoto T, Ishiguro N. Patient-reported outcomes as assessment tools and predictors of long-term prognosis: a 7-year follow-up study of patients with rheumatoid arthritis. Int J Rheum Dis 2015; 20:1193-1200. [DOI: 10.1111/1756-185x.12789] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- Masayo Kojima
- Department of Public Health Nagoya City University Graduate School of Medical Science; Nagoya University Hospital; Nagoya University School of Medicine; Nagoya Japan
| | - Toshihisa Kojima
- Department of Orthopedic Surgery and Rheumatology; Nagoya University Hospital; Nagoya University School of Medicine; Nagoya Japan
| | - Sadao Suzuki
- Department of Public Health Nagoya City University Graduate School of Medical Science; Nagoya University Hospital; Nagoya University School of Medicine; Nagoya Japan
| | - Nobunori Takahashi
- Department of Orthopedic Surgery and Rheumatology; Nagoya University Hospital; Nagoya University School of Medicine; Nagoya Japan
| | - Koji Funahashi
- Department of Orthopedic Surgery and Rheumatology; Nagoya University Hospital; Nagoya University School of Medicine; Nagoya Japan
| | - Shuji Asai
- Department of Orthopedic Surgery and Rheumatology; Nagoya University Hospital; Nagoya University School of Medicine; Nagoya Japan
| | - Yutaka Yoshioka
- Department of Orthopedic Surgery and Rheumatology; Nagoya University Hospital; Nagoya University School of Medicine; Nagoya Japan
| | - Kenya Terabe
- Department of Orthopedic Surgery and Rheumatology; Nagoya University Hospital; Nagoya University School of Medicine; Nagoya Japan
| | - Nobuyuki Asai
- Department of Orthopedic Surgery and Rheumatology; Nagoya University Hospital; Nagoya University School of Medicine; Nagoya Japan
| | - Toki Takemoto
- Department of Orthopedic Surgery and Rheumatology; Nagoya University Hospital; Nagoya University School of Medicine; Nagoya Japan
| | - Naoki Ishiguro
- Department of Orthopedic Surgery and Rheumatology; Nagoya University Hospital; Nagoya University School of Medicine; Nagoya Japan
| |
Collapse
|
37
|
Asai S, Takahashi N, Funahashi K, Yoshioka Y, Takemoto T, Terabe K, Asai N, Ishiguro N, Kojima T. Concomitant Methotrexate Protects Against Total Knee Arthroplasty in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors. J Rheumatol 2015; 42:2255-60. [PMID: 26428206 DOI: 10.3899/jrheum.150410] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/15/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVE To determine the effects of concomitant methotrexate (MTX) on the incidence of total knee arthroplasty (TKA) resulting from the progression of joint destruction in patients with rheumatoid arthritis (RA) during longterm treatment with tumor necrosis factor (TNF) inhibitors. METHODS A total of 155 patients with RA (310 knee joints) received TNF inhibitors at our institute between May 1, 2001, and May 31, 2008. A total of 111 symptomatic (tender and/or swollen) knee joints in 68 patients were retrospectively studied over the course of a minimum of 5 years of followup. The median (interquartile range) followup period was 8.1 (7.0-9.3) years. All data were analyzed using the knee joint as the statistical unit of analysis. TKA during treatment with TNF inhibitors was used as the outcome variable in predictive analyses. The cumulative incidence of TKA was compared by concomitant or no MTX use (MTX±). RESULTS There were 79 subjects (71%) who received concomitant MTX. According to Kaplan-Meier estimates, the cumulative incidence of TKA for the MTX+ group was significantly lower than that for the MTX- group (24% vs 45% at 5 yrs, respectively, p = 0.035). Multivariate analysis using the Cox proportional hazards model revealed that concomitant MTX (HR 0.44, 95% CI 0.22-0.89), Larsen grade (HR 2.93, 95% CI 1.94-4.41), and older age at baseline (HR 1.04, 95% CI 1.01-1.08) were independent predictors of TKA. CONCLUSION Concomitant MTX reduces the incidence of TKA by 56% in patients with RA during longterm treatment with TNF inhibitors.
Collapse
Affiliation(s)
- Shuji Asai
- From the Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.S. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Takahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Funahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; Y. Yoshioka, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Takemoto, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Terabe, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Ishiguro, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Kojima, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine.
| | - Nobunori Takahashi
- From the Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.S. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Takahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Funahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; Y. Yoshioka, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Takemoto, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Terabe, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Ishiguro, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Kojima, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine
| | - Koji Funahashi
- From the Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.S. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Takahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Funahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; Y. Yoshioka, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Takemoto, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Terabe, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Ishiguro, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Kojima, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine
| | - Yutaka Yoshioka
- From the Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.S. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Takahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Funahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; Y. Yoshioka, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Takemoto, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Terabe, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Ishiguro, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Kojima, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine
| | - Toki Takemoto
- From the Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.S. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Takahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Funahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; Y. Yoshioka, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Takemoto, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Terabe, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Ishiguro, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Kojima, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine
| | - Kenya Terabe
- From the Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.S. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Takahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Funahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; Y. Yoshioka, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Takemoto, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Terabe, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Ishiguro, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Kojima, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine
| | - Nobuyuki Asai
- From the Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.S. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Takahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Funahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; Y. Yoshioka, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Takemoto, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Terabe, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Ishiguro, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Kojima, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine
| | - Naoki Ishiguro
- From the Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.S. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Takahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Funahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; Y. Yoshioka, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Takemoto, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Terabe, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Ishiguro, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Kojima, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine
| | - Toshihisa Kojima
- From the Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.S. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Takahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Funahashi, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; Y. Yoshioka, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Takemoto, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; K. Terabe, MD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Asai, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; N. Ishiguro, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine; T. Kojima, MD, PhD, Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine
| |
Collapse
|
38
|
Moritani N, Matsumura T, Yamachika E, Goda Y, Uemura A, Nakata N, Tamura S, Yoshioka Y, Iida S. A novel guide device of the osteotomy line for intraoral vertical ramus osteotomy. Int J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.ijom.2015.08.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Togashi Y, Yoshioka Y, Chikugo T, Terashima M, Mizukami T, Hayashi H, Sakai K, Velasco MD, Tomida S, Fujita Y, Okuno K, Nishio K. 2169 Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinoma. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31089-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
40
|
Yoshioka Y, Takahashi N, Kaneko A, Hirano Y, Kanayama Y, Kanda H, Takagi H, Ito T, Kato T, Saito K, Funahashi K, Asai S, Takemoto T, Terabe K, Asai N, Ishiguro N, Kojima T. Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod. Mod Rheumatol 2015; 26:169-74. [PMID: 26140467 DOI: 10.3109/14397595.2015.1069475] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
OBJECTIVES This retrospective observational study aimed to examine the efficacy of iguratimod with and without concomitant methotrexate (MTX) and to estimate the adequate observational period for predicting low disease activity (LDA) achievement at 24 weeks in patients with rheumatoid arthritis (RA). METHODS All patients treated with iguratimod were registered in a Japanese multicenter registry. Multivariate analyses were performed to identify predictive factors for LDA achievement at 24 weeks. Receiver operating characteristic (ROC) curve analyses were performed to estimate the association of 28-joint disease activity score based on erythrocyte sedimentation rate (DAS28-ESR) at each time point with achievement of LDA at 24 weeks and determine a cut-off for DAS28-ESR. RESULTS A total of 123 patients were treated with iguratimod with (n = 65) or without (n = 58) MTX. Iguratimod therapy resulted in significant clinical improvement in both groups. Multivariate analysis revealed that DAS28-ESR at each time point was an independent significant predictor of LDA achievement at 24 weeks. Cut-off values of DAS28-ESR at 12 weeks based on ROC curves were 3.2 and 3.6 in patients with and without MTX, respectively. CONCLUSIONS Iguratimod was effective in RA patients in clinical practice. Our results suggest that 12 weeks may be a sufficient period to judge the medium-term efficacy of iguratimod in patients treated with and without MTX.
Collapse
Affiliation(s)
- Yutaka Yoshioka
- a Department of Orthopaedic Surgery and Rheumatology , Nagoya University Graduate School of Medicine , Aichi , Japan
| | - Nobunori Takahashi
- a Department of Orthopaedic Surgery and Rheumatology , Nagoya University Graduate School of Medicine , Aichi , Japan
| | - Atsushi Kaneko
- b Department of Orthopaedic Surgery and Rheumatology , Nagoya Medical Centre , Aichi , Japan
| | - Yuji Hirano
- c Department of Rheumatology , Toyohashi Municipal Hospital , Toyohashi , Japan
| | - Yasuhide Kanayama
- d Department of Orthopaedic Surgery , Toyota Kosei Hospital , Toyota , Japan
| | - Hiroyasu Kanda
- b Department of Orthopaedic Surgery and Rheumatology , Nagoya Medical Centre , Aichi , Japan
| | - Hideki Takagi
- e Department of Orthopaedic Surgery , Nagoya Central Hospital , Nagoya , Japan
| | | | | | | | - Koji Funahashi
- a Department of Orthopaedic Surgery and Rheumatology , Nagoya University Graduate School of Medicine , Aichi , Japan
| | - Shuji Asai
- a Department of Orthopaedic Surgery and Rheumatology , Nagoya University Graduate School of Medicine , Aichi , Japan
| | - Toki Takemoto
- a Department of Orthopaedic Surgery and Rheumatology , Nagoya University Graduate School of Medicine , Aichi , Japan
| | - Kenya Terabe
- a Department of Orthopaedic Surgery and Rheumatology , Nagoya University Graduate School of Medicine , Aichi , Japan
| | - Nobuyuki Asai
- a Department of Orthopaedic Surgery and Rheumatology , Nagoya University Graduate School of Medicine , Aichi , Japan
| | - Naoki Ishiguro
- a Department of Orthopaedic Surgery and Rheumatology , Nagoya University Graduate School of Medicine , Aichi , Japan
| | - Toshihisa Kojima
- a Department of Orthopaedic Surgery and Rheumatology , Nagoya University Graduate School of Medicine , Aichi , Japan
| |
Collapse
|
41
|
Tsukasaki Y, Komatsuzaki A, Mori Y, Ma Q, Yoshioka Y, Jin T. A short-wavelength infrared emitting multimodal probe for non-invasive visualization of phagocyte cell migration in living mice. Chem Commun (Camb) 2015; 50:14356-9. [PMID: 25296382 DOI: 10.1039/c4cc06542e] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
For the non-invasive visualization of cell migration in deep tissues, we synthesized a short-wavelength infrared (SWIR) emitting multimodal probe that contains PbS/CdS quantum dots, rhodamine 6G and iron oxide nanoparticles. This probe enables multimodal (SWIR fluorescence/magnetic resonance) imaging of phagocyte cell migration in living mice.
Collapse
Affiliation(s)
- Y Tsukasaki
- RIKEN Quantitative Biology Center, 6-2-3 Furuedai, Suita, Osaka 565-0874, Japan.
| | | | | | | | | | | |
Collapse
|
42
|
Kojima T, Takahashi N, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Watanabe T, Hayashi M, Shioura T, Kanayama Y, Funahashi K, Asai S, Yoshioka Y, Terabe K, Takemoto T, Asai N, Ishiguro N. THU0115 Importance of Both Disease Activity at 12 Weeks and Clinical Response up to 12 Weeks to Predict Achievement of Low Disease Activity at 52 Weeks During Abatacept Treatment in Biologics-Switching Patients with Rheumatoid Arthritis: A Multicenter Observational Cohort Study in Japan. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1318] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Asai S, Takahashi N, Funahashi K, Yoshioka Y, Takemoto T, Terabe K, Asai N, Ishiguro N, Kojima T. THU0078 Effects of Concomitant Methotrexate on the Long-Term Outcome of Knee Joint Destruction in Patients with Rheumatoid Arthritis Treated with Tumour Necrosis Factor Inhibitors. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Funahashi K, Kojima T, Takahashi N, Asai S, Yoshioka Y, Takemoto T, Terabe K, Asai N, Yabe Y, Ishiguro N. AB0466 The Outcome of Tocilizumab Treatment with Achievement of Glucocorticoids Withdrawal Against Rheumatoid Arthritis for 24 Months from TBC Registry. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
45
|
Kojima T, Takahashi N, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Watanabe T, Hayashi M, Shioura T, Kanayama Y, Funahashi K, Asai S, Yoshioka Y, Terabe K, Takemoto T, Asai N, Ishiguro N. AB0485 Predictive Factors for Achievement of Low Disease Activity or Remission at 52 Weeks in Switching from TNF Inhibitors to Abatacept with Background of low Dose or no Methotrexate: A Multicenter Observational Cohort Study in Japan. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
46
|
Kanayama Y, Hirano Y, Kaneko A, Takahashi N, Yoshioka Y, Kanda H, Hirabara S, Kojima T, Ishiguro N. THU0191 Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate: 52-Week Results – a Multicenter Registry Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
Mizuno H, Mizuno H, Sumida I, Otani Y, Yagi M, Takashina M, Suzuki O, Yoshioka Y, Koizumi M, Ogawa K. SU-E-T-767: Treatment Planning Study of Prostate Cancer by CyberKnife with Respect to the Urethral Dose. Med Phys 2015. [DOI: 10.1118/1.4925131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
48
|
Asai N, Yabe Y, Kojima T, Takahashi N, Funahashi K, Asai S, Takemoto T, Terabe K, Yoshioka Y, Ishiguro N. AB0476 Influence of the Reason for Discontinuation of Previous TNF Antagonists on the Retention of Tocilizumab. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
49
|
Yoshioka Y, Kozawa E, Urakawa H, Arai E, Futamura N, Zhuo L, Kimata K, Ishiguro N, Nishida Y. Inhibition of hyaluronan synthesis alters sulfated glycosaminoglycans deposition during chondrogenic differentiation in ATDC5 cells. Histochem Cell Biol 2015; 144:167-77. [DOI: 10.1007/s00418-015-1325-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/21/2015] [Indexed: 12/01/2022]
|
50
|
Shintani T, Hayashido Y, Mukasa H, Akagi E, Hoshino M, Ishida Y, Hamana T, Okamoto K, Kanda T, Koizumi K, Yoshioka Y, Tani R, Toratani S, Okamoto T. Comparison of the prognosis of bisphosphonate-related osteonecrosis of the jaw caused by oral and intravenous bisphosphonates. Int J Oral Maxillofac Surg 2015; 44:840-4. [PMID: 25861974 DOI: 10.1016/j.ijom.2015.03.013] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2014] [Revised: 03/13/2015] [Accepted: 03/23/2015] [Indexed: 01/03/2023]
Abstract
Bisphosphonates (BPs) have been used in medical practice for the treatment of osteoporosis, bone metastasis, and multiple myeloma. Although many studies have been published, the treatment and prognosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ) remain unclear. This study included 59 patients with BRONJ: 29 had taken oral BPs and 30 had taken intravenous (IV) BPs. All received conservative treatments. When separated sequestra were seen, a sequestrectomy was performed. Segmental mandibular resection was performed when pathological fractures were diagnosed. The outcomes of treatments were compared between groups. For patients treated with oral rinses or mandibular resection, the number in whom clinical healing was observed did not differ between the oral BP and IV BP groups. With regard to sequestrectomy, 94% of patients in the oral BP group showed improvement with this treatment compared to 50% in the IV BP group. The number of patients in whom clinical healing of BRONJ was achieved was statistically better in the oral BP group than in the IV BP group after 6 months of treatment (P<0.001). The results showed that >90% of patients treated with oral BPs could be cured. However, 50% of patients treated with IV BPs did not show an improvement. Additional research is needed to further increase the therapeutic efficacy for the resolution of BRONJ.
Collapse
Affiliation(s)
- T Shintani
- Centre of Oral Clinical Examination, Hiroshima University Hospital, Hiroshima, Japan.
| | - Y Hayashido
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - H Mukasa
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - E Akagi
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - M Hoshino
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Y Ishida
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - T Hamana
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - K Okamoto
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - T Kanda
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - K Koizumi
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Y Yoshioka
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - R Tani
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - S Toratani
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - T Okamoto
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| |
Collapse
|